JP7587921B2 - 抗クローディンタンパク質１８ａ２の抗体及びその応用 - Google Patents

抗クローディンタンパク質１８ａ２の抗体及びその応用 Download PDF

Info

Publication number
JP7587921B2
JP7587921B2 JP2019521178A JP2019521178A JP7587921B2 JP 7587921 B2 JP7587921 B2 JP 7587921B2 JP 2019521178 A JP2019521178 A JP 2019521178A JP 2019521178 A JP2019521178 A JP 2019521178A JP 7587921 B2 JP7587921 B2 JP 7587921B2
Authority
JP
Japan
Prior art keywords
seq
antibody
cell
cells
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019521178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531084A (ja
JP2019531084A5 (enExample
Inventor
ポン ワン，
ホア チアン，
リンリン ヤン，
チーミン シー，
ホアマオ ワン，
ツォンハイ リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crage Medical Co Ltd
Original Assignee
Crage Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/082024 external-priority patent/WO2017186121A1/zh
Application filed by Crage Medical Co Ltd filed Critical Crage Medical Co Ltd
Publication of JP2019531084A publication Critical patent/JP2019531084A/ja
Publication of JP2019531084A5 publication Critical patent/JP2019531084A5/ja
Application granted granted Critical
Publication of JP7587921B2 publication Critical patent/JP7587921B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019521178A 2016-07-08 2017-07-10 抗クローディンタンパク質１８ａ２の抗体及びその応用 Active JP7587921B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610536449.9 2016-07-08
CN201610536449 2016-07-08
PCT/CN2017/082024 WO2017186121A1 (zh) 2016-04-26 2017-04-26 一种改善免疫应答细胞功能的方法
CNPCT/CN2017/082024 2017-04-26
PCT/CN2017/092381 WO2018006882A1 (zh) 2016-07-08 2017-07-10 抗密蛋白18a2的抗体及其应用

Publications (3)

Publication Number Publication Date
JP2019531084A JP2019531084A (ja) 2019-10-31
JP2019531084A5 JP2019531084A5 (enExample) 2020-09-03
JP7587921B2 true JP7587921B2 (ja) 2024-11-21

Family

ID=60912336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019521178A Active JP7587921B2 (ja) 2016-07-08 2017-07-10 抗クローディンタンパク質１８ａ２の抗体及びその応用

Country Status (13)

Country Link
US (2) US11111295B2 (enExample)
EP (1) EP3483182B1 (enExample)
JP (1) JP7587921B2 (enExample)
KR (1) KR102723896B1 (enExample)
CN (1) CN109790222B (enExample)
AU (1) AU2017294276B2 (enExample)
BR (1) BR112019000327A8 (enExample)
CA (1) CA3030257A1 (enExample)
CL (1) CL2019000061A1 (enExample)
ES (1) ES2979068T3 (enExample)
IL (1) IL264144B2 (enExample)
SG (1) SG11201900171QA (enExample)
WO (1) WO2018006882A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000327A8 (pt) * 2016-07-08 2022-10-18 Carsgen Therapeutics Co Ltd Anticorpo para anticlaudina 18a2 e uso do mesmo
WO2019149279A1 (zh) 2018-02-02 2019-08-08 科济生物医药（上海）有限公司 细胞免疫治疗的组合
IL276830B2 (en) 2018-03-08 2025-08-01 Phanes Therapeutics Inc Anti-claudin 18.2 antibodies and uses thereof
CN119770648A (zh) * 2018-03-09 2025-04-08 克莱格医学有限公司 用于治疗肿瘤的方法和组合物
TW202003562A (zh) * 2018-03-14 2020-01-16 中國大陸商北京軒義醫藥科技有限公司 抗密連蛋白18.2(cldn18.2)抗體
US20220127570A1 (en) * 2018-05-03 2022-04-28 Cafa Therapeutics Limited Immune effector cell and use thereof
SG11202011392VA (en) 2018-05-15 2020-12-30 Carsgen Therapeutics Co Ltd Genetically engineered cell and application thereof
KR102421427B1 (ko) * 2018-05-18 2022-07-18 라노바 메디신즈 리미티드 컴파니 항-클라우딘 18.2 항체 및 이의 사용
EP3834849A4 (en) 2018-07-24 2022-08-03 CRAGE medical Co., Limited Method for treating tumor using immune effector cell
CN112770723B (zh) * 2018-07-25 2024-08-02 阿克罗斯生物科学公司 Cldn 18.2特异性单克隆抗体及其使用方法
CN110857322A (zh) * 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
WO2020043044A1 (zh) * 2018-08-27 2020-03-05 南京圣和药业股份有限公司 一种抗Claudin18.2抗体及其应用
CN109206524B (zh) * 2018-09-25 2022-04-05 山东兴瑞生物科技有限公司 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途
EP3858384A4 (en) * 2018-09-30 2022-07-06 CRAGE medical Co., Limited COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS
US20210380680A1 (en) * 2018-12-07 2021-12-09 ZLlP HOLDING LIMITED Anti-claudin antibodies and uses thereof
JP2022517301A (ja) 2018-12-07 2022-03-08 カファ セラピューティクス リミテッド 腫瘍併用免疫療法
CN113166246B (zh) * 2018-12-28 2024-10-18 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
KR20210110339A (ko) * 2018-12-28 2021-09-07 난징 진스크립트 바이오테크 컴퍼니 리미티드 클라우딘18.2 결합 모이어티 및 그 용도
CN113271953A (zh) * 2019-01-07 2021-08-17 科济生物医药（上海）有限公司 细胞免疫治疗的组合
CN113817061B (zh) * 2019-01-15 2022-11-04 浙江道尔生物科技有限公司 一种抗cld18a2单域抗体及其抗肿瘤用途
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN113490689B (zh) * 2019-02-01 2024-06-04 恺兴生命科技(上海)有限公司 Tcr融合蛋白及表达tcr融合蛋白的细胞
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN113661180B (zh) * 2019-03-27 2025-08-26 宾夕法尼亚大学董事会 Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
MX2021011887A (es) * 2019-03-29 2021-10-26 Phanes Therapeutics Inc Receptores de antigeno quimerico humanizados anti-claudin 18.2 y usos de los mismos.
US12428478B2 (en) * 2019-04-01 2025-09-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-Claudin 18.2 antibody and application thereof
CN119613553A (zh) * 2019-04-19 2025-03-14 康诺亚生物医药科技（成都）有限公司 肿瘤治疗剂及其应用
JP7407841B2 (ja) 2019-05-16 2024-01-04 斉魯制薬有限公司 クローディン１８ａ２に対する抗体及びその応用
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
EP3978532A4 (en) * 2019-05-24 2023-10-18 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
US12312402B2 (en) 2019-05-30 2025-05-27 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets Claudin 18.2
US12345709B2 (en) * 2019-07-17 2025-07-01 The Regents Of The University Of California CLAUDIN18 antibodies and methods of treating cancer
EP3853257A4 (en) * 2019-08-12 2022-06-29 I-Mab Biopharma US Limited Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
CN112574307B (zh) 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
PE20221459A1 (es) 2019-11-05 2022-09-21 Lanova Medicines Ltd Conjugados anticuerpo-farmaco dirigido a claudina 18.2
WO2021104511A1 (zh) * 2019-11-29 2021-06-03 苏州诺沃泰医药科技有限公司 Cart细胞在制备治疗癌症的药物中的应用
WO2021111003A1 (en) 2019-12-06 2021-06-10 SOTIO a.s. Humanized cldn18.2 antibodies
CN114901365B (zh) 2019-12-23 2025-07-15 斯迪安生物技术公司 肿瘤特异性密蛋白18.2抗体
EP4086287A4 (en) * 2020-01-03 2024-03-06 CRAGE medical Co., Limited ANTI-CLAUDIN 18.2 ANTIBODIES AND USE THEREOF
JP7522482B2 (ja) * 2020-02-10 2024-07-25 上海詩健生物科技有限公司 クローディン１８．２の抗体及びその使用
CN116096751A (zh) * 2020-02-25 2023-05-09 璟尚生物制药公司 三特异性t细胞接合器
KR20230012000A (ko) * 2020-05-15 2023-01-25 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 약물 컨쥬게이트, 이의 제조 방법 및 이의 용도
AU2021291259B2 (en) * 2020-06-19 2025-07-31 Fortvita Biologics (Singapore) Pte.Ltd. Anti-Claudin18.2 antibody and use thereof
CN111961135B (zh) * 2020-07-13 2022-08-16 北京亦庄国际蛋白药物技术有限公司 一种用于预防或治疗癌症的抗体
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
CN116194125A (zh) 2020-08-07 2023-05-30 克莱格医学有限公司 工程化改造的细胞以及工程化改造细胞的方法
KR20230078701A (ko) * 2020-09-30 2023-06-02 난징 진스크립트 바이오테크 컴퍼니 리미티드 인간 클라우딘 18.2를 표적화하는 항체 및 이의 용도
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
MX2023007384A (es) 2020-12-21 2023-07-05 Allogene Therapeutics Inc Car con puerta cd45 activado por proteasa.
KR20230124037A (ko) 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
US20220251505A1 (en) 2021-01-29 2022-08-11 Allogene Therapeutics, Inc. KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
CN117545771A (zh) * 2021-04-08 2024-02-09 克莱格医学有限公司 细胞免疫治疗的应用
WO2022218375A1 (zh) * 2021-04-15 2022-10-20 克莱格医学有限公司 嵌合t细胞受体及其应用
US20250269028A1 (en) 2021-06-29 2025-08-28 Carsgen Therapeutics Co., Ltd Chimeric polypeptide for regulating cell physiological activity
CN113788894B (zh) * 2021-09-03 2022-08-05 深圳市先康达生命科学有限公司 靶向人Claudin18.2蛋白的单克隆抗体及其应用
CN118139888A (zh) * 2021-11-05 2024-06-04 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
CN119677781A (zh) * 2022-05-06 2025-03-21 上海先博生物科技有限公司 靶向cldn18.2的嵌合抗原t细胞受体及其应用
CN120484126B (zh) * 2022-07-28 2025-11-18 乐普创一生物科技（上海）有限公司 抗MerTK抗体及其用途
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途
WO2025026347A1 (en) * 2023-07-31 2025-02-06 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and methods of use thereof
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN117430708B (zh) * 2023-12-21 2024-04-09 苏州近岸蛋白质科技股份有限公司 一种抗Claudin18.2抗体
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN120005046B (zh) * 2025-04-18 2025-09-02 深锐(天津)生物医学有限公司 双靶点嵌合抗原受体联合pd-1与il-21融合蛋白

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101312989A (zh) 2005-11-24 2008-11-26 加尼梅德药物公司 用于治疗癌症的针对密蛋白-18的单克隆抗体
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN104321345A (zh) 2012-05-09 2015-01-28 加尼梅德药物公司 用于癌症诊断的针对密蛋白18.2的抗体
WO2016008405A1 (zh) 2014-07-17 2016-01-21 科济生物医药（上海）有限公司 靶向cld18a2的免疫效应细胞及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
AU2016364853A1 (en) 2015-12-04 2018-06-21 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
WO2017186121A1 (zh) * 2016-04-26 2017-11-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
BR112019000327A8 (pt) * 2016-07-08 2022-10-18 Carsgen Therapeutics Co Ltd Anticorpo para anticlaudina 18a2 e uso do mesmo
CN119770648A (zh) * 2018-03-09 2025-04-08 克莱格医学有限公司 用于治疗肿瘤的方法和组合物
EP3858384A4 (en) * 2018-09-30 2022-07-06 CRAGE medical Co., Limited COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS
CN113271953A (zh) * 2019-01-07 2021-08-17 科济生物医药（上海）有限公司 细胞免疫治疗的组合
CN116348604A (zh) * 2020-08-10 2023-06-27 克莱格医学有限公司 多功能的免疫效应细胞及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101312989A (zh) 2005-11-24 2008-11-26 加尼梅德药物公司 用于治疗癌症的针对密蛋白-18的单克隆抗体
CN104321345A (zh) 2012-05-09 2015-01-28 加尼梅德药物公司 用于癌症诊断的针对密蛋白18.2的抗体
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016008405A1 (zh) 2014-07-17 2016-01-21 科济生物医药（上海）有限公司 靶向cld18a2的免疫效应细胞及其制备方法和应用

Also Published As

Publication number Publication date
US20190233511A1 (en) 2019-08-01
CA3030257A1 (en) 2018-01-11
BR112019000327A2 (pt) 2019-08-13
JP2019531084A (ja) 2019-10-31
ES2979068T3 (es) 2024-09-24
WO2018006882A1 (zh) 2018-01-11
AU2017294276A1 (en) 2019-02-28
US20220185880A1 (en) 2022-06-16
CN109790222A (zh) 2019-05-21
IL264144B1 (en) 2023-07-01
EP3483182B1 (en) 2024-05-08
IL264144B2 (en) 2023-11-01
EP3483182A4 (en) 2020-07-29
SG11201900171QA (en) 2019-02-27
US11111295B2 (en) 2021-09-07
KR20190038564A (ko) 2019-04-08
AU2017294276B2 (en) 2024-08-01
RU2019101430A (ru) 2020-08-10
NZ750420A (en) 2025-06-27
EP3483182A1 (en) 2019-05-15
CN109790222B (zh) 2022-03-15
IL264144A (en) 2019-02-28
KR102723896B1 (ko) 2024-11-01
BR112019000327A8 (pt) 2022-10-18
CL2019000061A1 (es) 2019-05-03
RU2019101430A3 (enExample) 2021-05-17

Similar Documents

Publication Publication Date Title
JP7587921B2 (ja) 抗クローディンタンパク質１８ａ２の抗体及びその応用
AU2021203790B2 (en) Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
ES2781175T3 (es) Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
US11530270B2 (en) Antibody targeting IL-13RA2 and use thereof
CN118146379A (zh) 一种改善免疫应答细胞功能的方法
WO2020020359A1 (en) Nef-containing t cells and methods of producing thereof
CN114616323A (zh) 包含nef的t细胞及其产生方法
WO2018149358A1 (zh) 靶向il-13ra2的抗体及其应用
RU2793445C2 (ru) Антитело против клаудина 18а2 и его применение
HK40002280B (zh) 抗密蛋白18a2的抗体及其应用
HK40002280A (zh) 抗密蛋白18a2 的抗体及其应用
HK40076251A (en) Engineered t cells and methods of producing thereof
HK40017077A (en) Il-13ra2-targeted antibody and application thereof
EA040145B1 (ru) Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210727

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220127

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220224

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220412

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220930

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221007

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221018

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221202

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241111

R150 Certificate of patent or registration of utility model

Ref document number: 7587921

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150